Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 21, 2026

Netflix (NFLX) Q4 2025 Earnings Call Transcript

View original at nasdaq.com
Netflix (NFLX) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. Date Tuesday, Jan. 20, 2026 at 4:45 p.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Netflix targets 2026 operating margin of 31.5%, up 2 percentage points including 0.5 point M&A expense headwind

    80% confidence
  • Post-launch party pack games (Boggle, Pictionary, LEGO) achieved approximately 10% reach into eligible members

    80% confidence
  • Ad-supported ARM is currently below ad-free ARM, representing a monetization gap

    80% confidence
  • Netflix 2025 operating margin reached 26%, raised from 25% guidance

    80% confidence
  • 2026 operating margin will be 2.5 points higher excluding M&A expenses

    80% confidence
  • Netflix retention is among the best in the industry

    80% confidence
  • Netflix targets $3 billion in ad revenue for 2026, doubling from 2025

    80% confidence
  • Netflix revenue grew 16% annually in 2025

    80% confidence
  • Netflix operates in 12 ad markets

    80% confidence
  • Netflix expects content amortization to increase 10% year-over-year in 2026

    80% confidence
  • Netflix historically expanded operating margin by approximately 2 percentage points annually on average

    80% confidence
  • Netflix primary quality metric reached all-time high in 2025

    80% confidence
  • There are 500+ million smart TV households globally that are non-Netflix members

    80% confidence
  • Netflix has less than 10% of TV time in all major markets

    80% confidence
  • Q2 2024 revenue growth was 17% reported

    80% confidence
  • Gaming market size is approximately $140 billion in consumer spend excluding China

    80% confidence
  • Q4 2025 churn improved year-over-year

    80% confidence
  • The Warner Bros. acquisition represents a tremendous, very achievable opportunity

    80% confidence
  • Netflix tested vertical video for approximately 6 months

    80% confidence
  • Live events represent a relatively small portion of total view hours

    80% confidence
  • Modular interactive video ads with dynamic templates completed testing in late 2025 with global rollout in 2026

    80% confidence
  • M&A expenses will create half a percentage point drag on operating margin in 2026

    80% confidence
  • Netflix forecasts 2026 revenue of $51 billion, representing 14% year-over-year growth

    80% confidence
  • Netflix ad revenue was 2.5x higher in 2025 compared to prior year

    80% confidence
  • Post-acquisition, 85% of Netflix revenue will come from current core businesses

    80% confidence
  • India ranked #2 and #3 for Netflix paid net adds and revenue growth in Q2 2024

    80% confidence
  • Customer satisfaction reached all-time high

    80% confidence
  • Theatrical distribution is a business decision that changes with conditions and insights, not a religious principle

    80% confidence
  • Warner Bros. global box office exceeds $4 billion

    80% confidence
  • Netflix executed 200+ live events

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com